ReviewSeminars in oncology2013
Molecular pathogenesis and progression of prostate cancer.
Review in Seminars in oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 135 citations in OpenAlex.
- Can Lycopene Impact the Androgen Axis in Prostate Cancer?: A Systematic Review of Cell Culture and Animal Studies.Nutrients · 2019Pooled it
- The prognostic significance of combined ERG and androgen receptor expression in patients with prostate cancer managed by androgen deprivation therapy.Cancer biology & therapy · 2014Trial
- Positron emission tomography (PET) imaging of prostate cancer with a gastrin releasing peptide receptor antagonist--from mice to men.Theranostics · 2014Trial
- LC-MS/MS and high-spatial single-cell MSI reveal selective downregulation of PC(16:0_16:0) and PC(18:0_18:1) due to mPGES-1 knockdown in hormone-resistant prostate cancer cell line.Analytical and bioanalytical chemistry · 2026Article
- Morphomechanically-Informed Spatial Curvature Sequencing in Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Development of In Situ Gelling Liquid Extended Release System for Oral Delivery of Abiraterone Acetate.AAPS PharmSciTech · 2026Article
- The molecular aspects in prostatic cancer, unraveling the role of CDKs in prostate cancer progression.Discover oncology · 2025Review
- Comparative analysis of 3D culture methodologies in prostate cancer cells.Experimental cell research · 2025Article
- Engineering the bone metastatic prostate cancer niche through a microphysiological system to report patient-specific treatment response.Communications biology · 2025Article
- Article
- Article
- PARP-ish: Gaps in Molecular Understanding and Clinical Trials Targeting PARP Exacerbate Racial Disparities in Prostate Cancer.Cancer research · 2024Review
- Review
- AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer.bioRxiv : the preprint server for biology · 2024Article
- Mesenchymal Stem Cell-Derived Extracellular Vesicles in Cancer Therapy Resistance: from Biology to Clinical Opportunity.International journal of biological sciences · 2024Review
- Role of Metabolism and Metabolic Pathways in Prostate Cancer.Metabolites · 2023Review
- Claudin-3 Loss of Expression Is a Prognostic Marker in Castration-Resistant Prostate Cancer.International journal of molecular sciences · 2023Article
- Prostate cancer cells demonstrate unique metabolism and substrate adaptability acutely after androgen deprivation therapy.The Prostate · 2022Article
- Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer.Frontiers in oncology · 2022Article
- Review
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Prostate cancer (PCa) is the most commonly diagnosed noncutaneous malignancy and second leading cause of cancer-related deaths in US males. Clinically, locally confined disease is treated surgically and/or with radiation therapy. Invasive disease, however, must be treated with pharmacological inhibitors of androgen receptor (AR) activity, since disease progression is fundamentally reliant on AR activation. However, despite initially effective treatment options, recurrent castration-resistant PCa (CRPC) often occurs due to aberrant reactivation of AR. Additionally, it is appreciated that many other signaling molecules, such as transcription factors, oncogenes, and tumor suppressors, are often perturbed and significantly contribute to PCa initiation and progression to incurable disease. Understanding the interplay between AR signaling and other signaling networks altered in PCa will advance therapeutic approaches. Overall, comprehension of the molecular composition promoting neoplastic growth and formation of CRPC is paramount for developing durable treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.